C-PRF With Minimally Invasive Non-Surgical Periodontal Therapy

August 18, 2026 updated by: Yusuf Cem Yavuz, Altinbas University

Clinical and Radiographic Evaluation of the Efficacy of Platelet-Rich Fibrin as an Adjunct to Minimally Invasive Non-Surgical Treatment in Individuals With Advanced Periodontitis

This randomized controlled clinical study evaluated whether concentrated platelet-rich fibrin (C-PRF) provides additional clinical and radiographic benefits when used together with minimally invasive non-surgical periodontal treatment (MINST) in patients with advanced periodontitis and intrabony periodontal defects.

Thirty systemically healthy patients with stage III-IV periodontitis were included. Each participant had at least one intrabony defect with a probing pocket depth of 6 mm or greater and a radiographic intrabony component of 3 mm or greater. Participants were randomly assigned to receive either MINST alone or MINST combined with C-PRF application.

Clinical periodontal measurements, including probing pocket depth, clinical attachment level, plaque score, bleeding on probing, and gingival recession, were recorded at baseline and at the 6-month follow-up. Standardized periapical radiographs were used to evaluate radiographic outcomes, including total defect depth, intrabony defect depth, defect angle, and linear bone fill.

Study Overview

Detailed Description

Periodontitis is a chronic multifactorial inflammatory disease associated with dysbiotic dental biofilm and progressive destruction of the tooth-supporting tissues. In advanced periodontitis, vertical alveolar bone loss may result in periodontal intrabony defects. These defects are clinically important because they are commonly associated with deep periodontal pockets, clinical attachment loss, bleeding on probing, and increased risk of further periodontal breakdown if not adequately treated.

The management of periodontal intrabony defects traditionally includes non-surgical periodontal therapy as the initial treatment approach. However, in advanced cases, residual deep pockets and persistent inflammation may remain after conventional non-surgical therapy. Minimally invasive non-surgical treatment (MINST) has been proposed as a tissue-preserving approach for the management of intrabony periodontal defects. MINST aims to remove subgingival biofilm and calculus through careful instrumentation while minimizing trauma to the periodontal tissues. The technique emphasizes the preservation of the interdental papilla and marginal gingiva, limited tissue manipulation, avoidance of aggressive root planing and gingival curettage, and support of stable blood clot formation within the defect.

In this study, MINST is performed using fine periodontal instruments and thin ultrasonic tips without flap elevation. The objective of this approach is to achieve effective subgingival debridement while preserving soft tissue architecture and supporting periodontal wound healing. The minimally invasive nature of the procedure may be particularly relevant for patients with advanced periodontitis, where maintaining gingival tissue stability and reducing postoperative morbidity are important clinical goals.

Platelet-rich fibrin (PRF) is an autologous platelet concentrate obtained from the patient's own blood. PRF contains platelets, leukocytes, fibrin, and growth factors that may contribute to wound healing, angiogenesis, tissue repair, and periodontal regeneration. Concentrated platelet-rich fibrin (C-PRF) is a liquid PRF formulation prepared by collecting the cell-rich fraction from the buffy coat layer after centrifugation. Compared with liquid PRF protocols, C-PRF is designed to provide a higher concentration of platelets and leukocytes in a small volume, potentially increasing its biological activity at the application site.

Although several studies have evaluated different adjunctive biomaterials with minimally invasive periodontal therapy, evidence regarding the use of C-PRF together with MINST in advanced periodontitis remains limited. Therefore, this study is designed to evaluate whether the adjunctive application of C-PRF may provide additional clinical and radiographic benefits when combined with MINST in patients with stage III-IV periodontitis and periodontal intrabony defects.

This is a single-center, prospective, randomized controlled clinical study conducted as part of a doctoral thesis in the Department of Periodontology at Altinbas University. A total of 30 systemically healthy participants diagnosed with stage III-IV periodontitis are included. Each participant has at least one periodontal intrabony defect with a probing pocket depth of 6 mm or greater and a radiographic intrabony component of 3 mm or greater.

Participants are randomly allocated into two treatment groups. The control group receives MINST alone. The test group receives MINST followed by adjunctive C-PRF application into the periodontal pocket associated with the selected intrabony defect. For C-PRF preparation, venous blood is collected from the patient and processed according to the C-PRF protocol. The concentrated liquid fraction is then applied locally into the periodontal pocket after completion of the MINST procedure.

Clinical periodontal measurements are recorded at baseline and at the 6-month follow-up. The evaluated clinical parameters include probing pocket depth, clinical attachment level, plaque score, bleeding on probing, and gingival recession. Measurements are performed using standardized clinical methods, and site-specific values are recorded for the selected intrabony defect sites.

Radiographic assessment is performed using standardized periapical radiographs. Customized radiographic stents are used to improve reproducibility of radiographic image acquisition between baseline and follow-up. Radiographic measurements include total defect depth, intrabony defect depth, defect angle, linear bone fill, and defect fill percentage. These measurements are used to evaluate changes in the morphology and depth of the intrabony defects over the 6-month follow-up period.

Patient-reported outcome measures are also evaluated using visual analogue scale scores. These assessments are included to evaluate patient-centered outcomes such as pain, satisfaction, and aesthetic perception following treatment.

Study Type

Interventional

Enrollment (Actual)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Bakırkoy
      • Istanbul, Bakırkoy, Turkey (Türkiye), 34147
        • Altınbaş University Faculty of Dentistry, Department of Periodontology

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Individuals aged 18 to 70 years.
  • Systemically healthy individuals.
  • Individuals diagnosed with Stage III or Stage IV periodontitis.
  • Presence of at least one periodontal intrabony defect with a radiographic intrabony defect depth of ≥3 mm.
  • Presence of probing pocket depth of ≥6 mm at the selected defect site.
  • No periapical pathology associated with the selected tooth.

Exclusion Criteria:

  • Pregnancy or lactation.
  • Presence of systemic diseases or use of medications that may affect periodontal healing.
  • Periodontal treatment within the recent period before enrollment.
  • Smoking ≥10 cigarettes per day.
  • Presence of periapical pathology associated with the selected tooth.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: MINST Alone
Participants in this arm received minimally invasive non-surgical periodontal treatment (MINST) alone for the selected periodontal intrabony defect. Subgingival debridement was performed using fine ultrasonic tips and mini-curettes without flap elevation, with the aim of removing biofilm and calculus while preserving soft tissue architecture and supporting periodontal wound healing.
Minimally invasive non-surgical periodontal treatment was performed for the selected periodontal intrabony defect without flap elevation. Subgingival debridement was carried out using fine ultrasonic tips and mini-curettes. The procedure aimed to remove subgingival biofilm and calculus while preserving the interdental papilla, marginal gingiva, and soft tissue architecture, and supporting stable blood clot formation within the defect.
Other Names:
  • MINST
Active Comparator: MINST With C-PRF
Participants in this arm received minimally invasive non-surgical periodontal treatment (MINST) followed by adjunctive application of concentrated platelet-rich fibrin (C-PRF) into the periodontal pocket associated with the selected intrabony defect. C-PRF was prepared from the participant's own venous blood and applied locally after completion of the minimally invasive debridement procedure.
Minimally invasive non-surgical periodontal treatment was performed for the selected periodontal intrabony defect without flap elevation. Subgingival debridement was carried out using fine ultrasonic tips and mini-curettes. The procedure aimed to remove subgingival biofilm and calculus while preserving the interdental papilla, marginal gingiva, and soft tissue architecture, and supporting stable blood clot formation within the defect.
Other Names:
  • MINST
Concentrated platelet-rich fibrin was prepared from the participant's own venous blood according to the C-PRF protocol. After centrifugation, the concentrated liquid fraction was collected from the buffy coat region and applied locally into the periodontal pocket associated with the selected intrabony defect following completion of minimally invasive non-surgical periodontal treatment.
Other Names:
  • C-PRF

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in probing pocket depth (PPD)
Time Frame: Baseline and 6 months
Change in probing pocket depth (PPD) at the selected intrabony defect site from baseline to 6 months. PPD will be measured in millimeters using a UNC-15 periodontal probe.
Baseline and 6 months
Change in clinical attachment level (CAL)
Time Frame: Baseline and 6 months
Change in clinical attachment level (CAL) at the selected intrabony defect site from baseline to 6 months. CAL will be measured in millimeters using a UNC-15 periodontal probe.
Baseline and 6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in radiographic intrabony defect depth
Time Frame: Baseline and 6 months
Change in radiographic intrabony defect depth (IDD) from baseline to 6 months, measured on standardized periapical radiographs.
Baseline and 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 2, 2026

Primary Completion (Estimated)

February 9, 2027

Study Completion (Estimated)

February 9, 2027

Study Registration Dates

First Submitted

July 3, 2026

First Submitted That Met QC Criteria

July 9, 2026

First Posted (Actual)

July 10, 2026

Study Record Updates

Last Update Posted (Actual)

August 19, 2026

Last Update Submitted That Met QC Criteria

August 18, 2026

Last Verified

August 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data will not be shared because the data contain confidential clinical information and were collected under ethical approval and informed consent for the purposes of this study only.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe